Characterization of Clinical Skeletal and Cardiac Impairment in Carriers of DMD and BMD
Characterization of Clinical Skeletal and Cardiac Impairment in Carriers of Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Kate Kanwar, MS
- Phone Number: 614-355-5649
- Email: Kate.kanwar@nationwidechildrens.org
Study Contact Backup
- Name: Victoria Shay, MS
- Phone Number: 615-355-5819
- Email: victoria.shay@nationwidechildrens.org
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43205
- Nationwide Children's Hosptial
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age >18 years
- Cohort A requires a genetically confirmed mutation in the DMD gene with an affected child
- Cohort B includes DMD/BMD mothers with NO somatic mutation in the DMD gene
- Cohort C age-matched healthy controls with a normal CK level
- Cohort D requires a genetically confirmed mutation in the DMD gene without an affected child
- Able to complete testing in English
- Able to consent
Exclusion Criteria:
- Subjects with a contraindication to cardiac or skeletal muscle MRI
- Subjects on heart failure medication at time of enrollment
- Subjects on steroid treatment
- Presence of an inherited neurologic disease or comorbidity that may affect their ability to complete this study
- Has a medical condition or extenuating circumstance that, in the opinion of the investigator, might compromise the subject's ability to comply with the protocol required testing or procedures or compromise the subject's wellbeing, safety, or clinical interpretability
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Cohort A
DMD/BMD Female Carriers who have/had an affected child (n=150)
|
Confirmatory genetic testing for mutation in DMD gene (Carrier Status) for subjects in respective Cohorts
|
|
Cohort B
DMD/BMD Female non-carriers controls who have/had an affected child (n=50)
|
Confirmatory genetic testing for mutation in DMD gene (Carrier Status) for subjects in respective Cohorts
|
|
Cohort C
Healthy Age-Matched Controls (n=50)
|
Confirmatory genetic testing for mutation in DMD gene (Carrier Status) for subjects in respective Cohorts
|
|
Cohort D
DMD/BMD Female Carriers with no affected children (n=25)
|
Confirmatory genetic testing for mutation in DMD gene (Carrier Status) for subjects in respective Cohorts
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Compromise of cardiac function based on Cardiac Magnetic Resonance Imaging
Time Frame: 2 years
|
Cardiac function as compromised by evidence of scarring of cardiac muscles, particularly of the base of the left ventricle via cardiac MRI studies with gadolinium contrast.
|
2 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cardiac Function Assessment Treadmill SVO2
Time Frame: 2 years
|
Stress on heart muscle measured by SVO2 (percentage of oxygen saturation in the blood of the pulmonary artery).
SVO2 represents an average of all the venous oxygen saturation of major organs and tissues.
This measure provides assessment of cardiopulmonary function and helps measure the degree of cardiac instability and can be an indicator of deterioration from normal.
|
2 years
|
|
Physical Therapy Assessments Maximum Voluntary Isometric Contraction Testing
Time Frame: 2 Years
|
MVICT measures strength of skeletal muscles by assessing the force generated by by individual muscles.
The results can be compared to norms and deterioration can be assessed over time.
|
2 Years
|
|
Physical Therapy Assessments 6 Minute Walk Test
Time Frame: 2 years
|
A timed test to assess distance walked in 6 minutes is very quantitative and can be assessed in comparison to normal controls.
Deterioration over time can be clearly measured.
|
2 years
|
|
Physical Therapy Assessments ACTIVE-seated
Time Frame: 2 Years
|
Exploratory outcome quantifying upper extremity reaching ability using a custom-designed game telling how far the arm reaches in comparison to overall functional ability of the individual ability.
|
2 Years
|
|
Physical Therapy Assessments Time-to-Rise
Time Frame: 2 Years
|
A timed-test to measure ability to rise from the floor is quantifiable and measuring over time tells if there is loss of function.
|
2 Years
|
|
Laboratory biomarkers - Creatine Kinase
Time Frame: 2 Years
|
CK levels are an indicator of muscle breakdown.
|
2 Years
|
|
Laboratory biomarkers - C-Reactive Protein
Time Frame: 2 Years
|
Pro-inflammatory marker indicating the degree of inflammation of muscle when there is muscle breakdown.
|
2 Years
|
|
Laboratory biomarkers - Interleukin-6
Time Frame: 2 Years
|
Pro-inflammatory marker indicating the degree of inflammation of muscle when there is muscle breakdown.
|
2 Years
|
|
Laboratory biomarkers - Cortisol levels
Time Frame: 2 Years
|
Hair cortisol levels measure stress levels as a means of understanding coping with disease.
|
2 Years
|
|
Cognitive Assessment
Time Frame: 2 Years
|
Cognitive function measured by Wechsler Abbreviated Scale of Intelligence (WASI) provides a possible tool to measure disease awareness and establish if IQ level correlates with disease-related stress.
|
2 Years
|
|
Caregiver Stress
Time Frame: 2 Years
|
Online self-report survey to assess stress burden on caregiver.
|
2 Years
|
|
Pulmonary function testing (PFTs)
Time Frame: 2 Years
|
Stable or improved FVC
|
2 Years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: May Ling Mah, MD, PI
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB16-00319
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.